An Update on New Vaccines for Tuberculosis

Afshan Sumera, Leong Chia Inn, Ankur Barua
2016 Journal of Asian Scientific Research  
Tuberculosis (TB) is one of the most common and deadly communicable diseases in the world , infecting approximately one-third of the total human race. The number of drug-resistant TB cases are increasing. The spectrum of resistance varies from single to multidrug and from multidrug to total drug resistance varieties. Human Immunodeficiency Virus (HIV) infection is also responsible for the recent re-emergence of tuberculosis infection worldwide. When drugs are becoming ineffective against
more » ... tive against Mycobacterium tuberculosis, there is a need to focus more on preventive strategies. Though Bacillus Calmette-Guérin (BCG) vaccine is efficient in preventing miliary and meningeal tuberculosis in children, it is not effective against pulmonary tuberculosis. For prevention of pulmonary tuberculosis, development of new vaccines is the need of time. Several new vaccines are under clinical trials either to replace old BCG or act as a booster for the current BCG vaccine. New vaccines include live Mycobacterial vaccines, its subunit, live vector-based vaccines and killed whole or fragmented vaccines. This review recaps the status of development of pre-clinical tuberculosis vaccines. This study reviews current knowledge regarding the status of development of new vaccines for tuberculosis.
doi:10.18488/journal.2/2016.6.3/2.3.41.47 fatcat:longeyla6jb3fg7vpe4wvf4c3a